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Summun- In a cohort of women aged 40-64 at entry. 12 h urine samples were obtained at the beginning of a
follow-up period of up to 15 years in which incident cases of lung cancer were registered as well as deaths
from lung cancer. In this cohort a nested case-control study (n = 397) was carried out by measuring urinary
cotinine. The method for quantitation of cotinine was sensitive enough to study lung cancer risk not only in
active smokers but also in passive smokers. The results seem to indicate that cotinine estimations in singJe 12 h
"mnlec- of iurine nre enoiah to nredirt tlne "ncrr ricsk Relative riKk rnqce with inerecit1n levelsk of nientinetrieved from the cancer registry. and two controls per case
were selected by computer for comparison. Urine samples
retrieved in the second and third waves were analysed in
1992.
Thus, the material for biochemical analysis consisted of
urine samples from 92 lung cancer cases and 305 controls
among two populations of women at risk of lung cancer over
the years 1977-91 and 1988-91.
Anal)tical method
At the National Institute of Public Health and Environmen-
tal Protection, Bilthoven (The Netherlands) urine concentra-
tions of cotinine were measured by a capilllary gas
chromatography-mass spectrometry (GC-MS) method. In
brief the method of analysis was as described below.
To a 5ml aliquot of urine, I ml of I mol I- 1 sodium
hydroxide and 1 Lg of internal standard (100pl to a
10 ng ld' solution) were added and the mixture was trans-
ferred to an octadecyl (C18) silica solid-phase extraction
column, which was preconditioned with 1 ml of methanol
and 1 ml of sodium borate buffer (0.05 mol 1-1; pH 9.0).
After washing the column with 4 ml of sodium borate buffer
and 100 gl of methanol, the analytes were eluted with 350gll
of methanol. To this eluate 350 lal of methylene chloride and
100 gil of sodium borate buffer were added. After mixing and
centrifuging at 2000g for 2 min the organic layer was col-
lected and evaporated to dryness at 40°C under a mild stream
of nitrogen. The residue was redissolved in 100;l of
triethylamine solution (I mmol 1- triethylamine in dichlo-
roethane).
GC-MS analyses were performed using electron ionisation
on a Varian 3400 gas chromatograph with a Finnigan MAT
Incos 500 mass selective detector (Finnigan MAT, Veenen-
daal, The Netherlands). A fused silica permabond SE-52
GC-column, 25 m x 0.25 mm ID, film thickness 0.25 gm
(Gimex, Geldermalsen. The Netherlands) was used. The col-
umn oven temperature was programmed from 80°C (after a
1 min hold) to 300'C rate of temperature increase
20'C min- . final hold 3mn. The injector and transferine
temperatures were 240°C and 275'C respectively. The sample
(1 pi) was injected using a Finnigan MAT A200S autosamp-
ler.
Two calibration curves (concentration range
0.5-250ngml-' and 250-2500 ngml-') were constructed by
plotting the peak height ratios (cotinine-cotinine-d3; ions
176:179) against the cotinine concentrations.
The limit of detection was 0.5 ngml-'. The between-days
variability for the concentration range 0.5-30ngml-l was
20-40%, depending on the concentration (n = 10). The
between-days variability at a level of 100ngml-' cotinine
was 10% (n= 10).
The measurement of the creatinine concentrations was
done automatically by the Jaffe alkaline picrate reaction,
using the COBAS BlO centrifugation-analyser. (Roche Diag-
nostic Systems, Mijdrecht, The Netherlands). The within-day
variation was 2% and the between-days variation was 3%
for concentrations between 0.5 and 15 mmol -1.
Data analysis
At the Department of Epidemiology. University of Utrecht.
data analysis was performed with an Olivetti PCS 33 using
SPSS version 4.0.1.
To explore the relationship between lung cancer risk and
cotinine excretion values which reflects presumably the com-
plete range of nicotine intakes, we divided the declared non-
smokers as well as the smokers into tertiles of cotinine
excretion. Odds ratios of strata for active smokers relating to
lung cancer risk were calculated, defining the sum of the
passive smokers and non-smokers as the reference group. To
calculate the odds ratios of the strata relating to lung cancer
risk for passive smokers, we defined the lowest tertile of the
non-smokers as the reference group. The two highest tertiles
of the non-smoking group were defined as passive smokers.
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Odds ratios were also calculated for different types of lung
carcinoma.
In all analyses subjects with unreported cigarette consump-
tion were excluded.
Results
Urinary excretion ofcotinine according to declared smoking
habits
The frequency distributions of urinary logarithmically trans-
formed urinary cotimnne concentrations of all women (cont-
rols plus cases) according to their declared smoking status at
the time of urine collection are shown in Figure 1. Clearly
there exists a high degree of association between their self-
reported smoking status and the objective tests of cotinine
excretion.
Comparing the distribution of urinary cotimne concentra-
tions with declared smoking status (Figure 1) indicated that
the optimal cut-off point for distinguishing between active
smokers on the one hand and passive smokers and non-
smokers on the other hand was at a level of 70 ng ml-' (log,0
70 being 1.85).
In order to allow for the influence of diuresis we have
expressed the cotinine results not only as concentrations per
ml of urine but also in the form of ratios on a creatinine
basis. The correlation between both ways of expressing
results is high (r = 0.97. 95% CI 0.96-0.97). The best cut-off
point between smokers and non-smokers proved to be
100 ng mg-' of creatinine with a sensitivity of 91% and a
specificity of 97% (questionnaire data acting as golden stan-
dard).
From a sample of 167 women (those representing the first
wave of cases and controls: see Methods) cotinine has been
measured in urine collected at two different points over time.
with a 1 year interval. The Pearson correlation coefficient of
the relation between the two samples concerning log cotimnne
(in ng mg' creatinine) proved to be high (r = 0.88, 95% CI
0.83-0.91); above the level of 100 ng mg-' creatinine it was
0.79 (95% CI 0.62-0.89). below that level it was 0.49 (95%
CI 0.32-0.64).
Cotinine excretion and lung cancer risk
In investigating the relationship between the urinary excre-
tion of cotinine and lung cancer risk a breakdown of
exposures has been chosen so as to allow the study of lung
cancer risk not only among active smokers but also among
passive smokers. Thus three levels below 100 ng cotinine per
mg creatinme and three levels above that point were distin-
guished. The results are shown in Tables I and II. The data
show a clear trend of increasing lung cancer risk with rising
cotinine excretion. The increased risk also appears to begin at
levels of nicotine intake in the passive smoking range (Table
II). It was found that adjusting for creatinine resulted in
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Figure I Frequency distribution of log cotinine concentration
according to declared smoking status at time of urine collection
(lung cancer cases included). M. smokers: =l. non-smokers.Cofinme and lung uncer risk
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Table I Risk of lung cancer according to unnary excretion of
cotimne in active smokers
Lrinary cotinine inngmg-'
creatinine. range Lung cancer Odds ratio
(geometric mean, cases Controls (950% CI)
<io0a (13) 23 191 1.0
100-900 (372) 5 32 1.3 (0.5-3.7)
901-2251 (1429) 21 17 10.3 (4.7-22.2)
2260-7345 (3184) 20 17 9.8 (4.5-21.3)
All smokers (1194) 46 66 5.8 (3.3-10.3)
Total 69 257
adefinition for passive smokers and non-smokers.
Table II Risk of lung cancer according to unnary excretion of
cotimne in passive smokers
Crinar coinine in ngmg-I
creatinine: range Lung cancer Odds ratio
(geometric meanj cases Controls (95% CI,
<9.2 (3.6) 4 67 1.0
9.2-23.4 (14.9) 10 62 2.7 (0.8-9.1)
23.4-100 (41.8) 9 62 2.4 (0.7-8.3)
Total 23 191
somewhat higher odds ratios concerning lung cancer risk
than without such adjustment (data not shown).
The lung cancer distribution between the different levels of
self-reported cigarette consumption did not differ significantly
(P = 0.14; r' test) from the one of the corresponding cotinine
categories. Urinary cotinine did not seem to be more predic-
tive of lung cancer risk than self-reported cigarette consump-
tion.
Histological tipe and lung cancer risk in relation to smoking
Data on histological type of lung cancer were available
through the cancer registry for 49 of the patients (see Table
III). Relative risk in relation to cotimine excretion was com-
puted separately for adenocarcinoma in contrast to the sum
of other histological types.
The results presented in Table IV show that the relation-
ship with smoking is much weaker for adenocarcinoma of the
lung than for the other pulmonary cancers. In fact, an odds
ratio significantly above 1 was found only at fairly high levels
of nicotine intake.
Discussion
This is believed to be among the first studies of its kind to
establish a relationship between exposure to tobacco smoke
and lung cancer risk by direct and objective methods, i.e.
measuring cotinine in urinary samples from a cohort of
women followed for a period of up to 15 years. The results
confirm recent insight that lung cancer risk ratios according
to amount smoked are equally high in women as in men
(Garfinkel and Stellman. 1988: Osann et al., 1993). Unfor-
tunately. no personal data were available on the duration of
smoking by the women of the cohort. However, we have
reason to believe that they are from a generation which
began smoking immediately after World War II (when they
were 20-35 years of age). and the high relative risks of lung
cancer experienced by the smokers during the years 1977-91
seem to substantiate this belief.
A salient aspect of the present paper is concerned with the
possible risk of environmental tobacco smoke. The results of
this study seem to indicate that there is not only a very high
lung cancer risk associated with active smoking as expressed
by high levels of cotinine excretion but also a modest in-
crease of risk at levels of cotinine associated with passive
smoking. The relative nrsk in passive smokers according to
our classification (having a reference group with a minimal
Table MII Frequency distribution of lung carcinoma by histological
subtype (cancers reported to the Cancer Registry)
Cases
Histological subtspe n %
Adenocarcinoma 22 45
Small-cell carcinoma 13 27
Squamous cell carcinoma 8 16
Carcinoid 3 6
Other 3 6
Total 49 100
Table IV Odds ratios in relation to cotinine excretion for different
types of lung cancer
Cotinine (ngmg-'
creatinineJ
OR adenocarcinomas OR other carcinomas
(95% CI, (950% CI,
< 10a 1.0 1.0
100-900 0.3 (0.0-2.2) 4.7 (1.1 -20.1)
901-2251 12.4 (2.3-67.1) 9.3 (2.5-34.8)
2260-7345 3.1 (0.4-24.6) 15.2 (4.2-54.7)
All smokers 2.1 (0.8-5.9) 9.3 (3.4-25.9)
'definition for passive smokers and non-smokers. OR. odds ratios.
cotinine excretion) was found to be of the order of 2 to 3
rather that 1.3 or 1.5 (the meta-estimate by Wald et al.. 1986)
but the confidence intervals are wide (Table II). It is more in
line with the relatively high estimates published by Garfinkel
et al. (1985). Pershagen et al. (1987) and some of the papers
mentioned by Blot and Fraumeni (1986).
With our GC-MS method. cotimine excretion measure-
ments were slightly higher than those reported by some
others (Jarvis et al.. 1984; Wald et al., 1984; Wall et al., 1988;
Haley et al., 1989). However, they were much lower than
those reported by Matsukura et al. (1984). It should be borne
in mind that excretion levels corrected for creatinine excre-
tion are affected by gender since women have less muscle
mass then men.
The question could be raised whether cotinine levels reflect
passive smoking (Idle, 1984). However. Jarvis et al. (1984),
Wald et al. (1984), Haley et al. (1989). Riboli et al. (1990)
and Cook et al. (1994) have shown that in non-smokers
elevated cotinine levels are directly related to an increased
environmental exposure to tobacco smoke. In a recent study
Hecht et al. (1993) found a high correlation between urinary
cotinine and a powerful tobacco-specific lung carcinogen.
There is no reason to believe that the women were lying
about their smoking habits when they were visiting the
screening facility in good health. Biochemical errors are
unlikely since the method of cotinine determination is very
specific. We rule out any genetic traits to produce cotinine
naturally. Theoretically, cotinine excretion due to the con-
sumption of vegetables could complicate the interpretation of
our study. However, cotinine exposure from vegetables is
greatly reduced when vegetable skins, which contain most of
the nicotine, are not eaten or cooked in water, thereby
extracting the nicotine. Moreover, absorption of nicotine
from the stomach is poor and 70% of it is metabolised
during its first pass through the liver (Henningfield, 1993).
Thus the most likely explanation of low levels of urinary
cotinine is exposure to environmental tobacco smoke.
Since cotimnne excretion levels obtained at intake in the
cohort correlated well with those obtained 1 year later, there
is objective evidence for the notion that these levels reflect
the chronic smoking habits of the persons concerned and the
relative constancy of levels of tobacco smoke in their
immediate human environment. Jarvis et al. (1987) came to a
similar conclusion after studying cotinine in saliva. It was
shown by an independent laboratory that cotinine in the
unnary samples of our 'bank' (which were kept frozen at
-20°C) did not deteriorate over a period of 9 years (Riboli
et al., 1995).Cotinir and lung cancer risk
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In our study, urinary cotinine did not seem to be more
predictive of lung cancer, than self-reported cigarette con-
sumption. This was not surprising since the urine samples
and data about reported cigarette comsumption were col-
lected before the risk of smoking in women became an
important issue, and therefore probably very reliable. Unfor-
tunately, no information was solicited concerning self-
reported passive smoke exposure since data from the ques-
tionnaires were collected long before the first papers on that
issue were published. So. it was not possible to study whether
cotinine is more predictive of lung cancer risk than self-
reported passive smoke exposure. However, there is an
advantage of having an objective test of exposure to tobacco
smoke instead of a questionnaire about hours of passive
smoke exposure in non-smokers.
The present paper confirms results published by others
(Kreyberg, 1954; Trichopoulos et al.. 1981; Damber and
Larson, 1986; Koo et al.. 1987; Pershagen et al.. 1987;
Osann, 1991; Brownson et al., 1992) on the relationship
between smoking and adenocarcinoma of the lung; it is much
weaker than that of other histological types. In fact, no
relationship between adenocarcinoma and passive smoking
was apparent from the data. The relatively high proportion
of adenocarcinoma found in this cohort is in agreement with
the relatively low percentage of smokers (30); the smoking-
related epidemic of lung cancer in women probably is only at
its beginning.
In this study a direct and objective method is used to
explore the relationship between exposure to tobacco smoke
and lung cancer risk. There is some advantage in an app-
roach which does not require either histories of active smok-
mg or histories concerning possible exposure to environmen-
tal tobacco smoke.
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